Reconciliation of IP, in clinical research, refers to the process of accounting for all investigational product (IP) throughout a clinical trial. This involves tracking the quantity of IP received, dispensed, returned, and destroyed, ensuring that all units are accounted for and any discrepancies are identified and explained.
The reconciliation process is crucial for maintaining regulatory compliance and ensuring the integrity of clinical trial data. It typically occurs at regular intervals during the study and at the conclusion of the trial, with the aim of verifying that the IP has been handled and administered according to the study protocol.
Reconciliation of IP is crucial for maintaining the integrity and validity of clinical trial data. It ensures that all investigational products are properly accounted for, which is essential for regulatory compliance and the accurate assessment of drug efficacy and safety.
This process also helps in detecting and preventing potential errors or misconduct in drug handling and administration. By providing a clear audit trail, reconciliation of IP supports the overall quality and credibility of the clinical research, which is vital for the eventual approval and marketing of new drugs.
The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Copyright @ 2026 Axcellant